Sort
10,766 grants matching “checkpoint inhibitor”
Targeting novel therapeutic vulnerabilities in LKB1 mutant tumors.
$677,471Nabeel Bardeesy · Massachusetts General Hospital · R01 · FY2020 · CA
Targeting novel therapeutic vulnerabilities in LKB1 mutant tumors.
$677,442Nabeel Bardeesy · Massachusetts General Hospital · R01 · FY2021 · CA
Tissue-based biomarkers of anti-PD-1-based therapy in metastatic renal cell carcinoma
$677,362Toni Choueiri · Dana-Farber Cancer Inst · R01 · FY2024 · CA
Targeting Non Viral Markers of HIV Persistence
$677,215Timothy Jensen Henrich · University Of California, San Francisco · R01 · FY2019 · AI
Targeting the CD73-adenosinergic pathway in head and neck cancer
$677,163Yan Cui · Augusta University · R01 · FY2025 · DE
A Registry-Based Study of Patterns of Use of Targeted Therapies for Metastatic Cancers in Diverse Populations
$676,657Christine Veenstra · University Of Michigan At Ann Arbor · R37 · FY2021 · CA
Integrated blood and radiomic subtyping to guide immunotherapy treatment selection and early response assessment in metastatic non-small cell lung cancer
$676,561Natalie Vokes · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
Prebiotic diet intervention to enhance the microbiome and immunotherapy response in melanoma
$676,478Carrie Daniel-Macdougall · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Assessing benefits and harms of cannabis use in patients treated with immunotherapy for cancer: a prospective cohort study
$676,418Rebecca Ashare · State University Of New York At Buffalo · U01 · FY2023 · CA
Development of Physiologic Tissue Models to Assess Tumor Explant Response to Immune Checkpoint Blockade
$676,329Roger D. Kamm · Massachusetts Institute Of Technology · U01 · FY2020 · CA
Defining immune-evasive mechanical signaling in head and neck cancer
$676,314Xaralabos Varelas · Boston University Medical Campus · R01 · FY2025 · DE
Synthetic lethal targeting of EBV-positive diffuse large B cell lymphomas in persons living with HIV
$676,145Sumita Bhaduri-McIntosh · University Of Florida · U01 · FY2025 · CA
A single-arm phase II study to evaluate the safety and efficacy of combination systematic chemotherapy and multiple rounds of endoscopic ultrasound-guided radiofrequency ablation in pancreatic cancer
$676,081Jennifer Bailey Lundberg · University Of Texas Hlth Sci Ctr Houston · R01 · FY2023 · CA
Early identification of immunotherapy resistance through integrated multiparameter imaging
$676,006Mekhail Anwar · University Of California, San Francisco · R01 · FY2025 · CA
Detection of PD-1 inhibitory signaling and its molecular relays in T cells: Implications for cancer immunotherapy
$675,994Vassiliki A Boussiotis · Beth Israel Deaconess Medical Center · R01 · FY2024 · CA
Radiation-induced translational control of gene expression
$675,650Philip Tofilon · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA
Exploiting the VISTA Pathway to Prevent Acute GVHD and Control Steroid Refractory Disease
$675,176Bruce R. Blazar · University Of Minnesota · R01 · FY2021 · HL
Rewiring T cell exhaustion with immune checkpoint blockade therapy
$674,996Linda Mac Pherson Bradley · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2025 · CA
Rewiring T cell exhaustion with immune checkpoint blockade therapy
$674,996Linda Mac Pherson Bradley · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2024 · CA
Enhancing cell therapy for brain tumors
$674,256Catherine Mary Bollard · Children'S Research Institute · U01 · FY2018 · CA
N-glycosylation and Immunotherapy for cancer
$673,731Michael Demetriou · University Of California-Irvine · U01 · FY2021 · CA
N-glycosylation and Immunotherapy for cancer
$673,731Michael Demetriou · University Of California-Irvine · U01 · FY2022 · CA
Project 1: Multi-scale modeling of adaptive drug resistance in BRAF-mutant melanoma
$673,611Peter Karl Sorger · Harvard Medical School · U54 · FY2020 · CA
CD200R blockade for cancer immunotherapy
$673,569Sujit Basu · Ohio State University · R01 · FY2025 · CA
Synthetic lethalities to cell cycle disruption in glioma
$673,491Rameen Beroukhim · Dana-Farber Cancer Inst · R01 · FY2025 · CA